Switzerland
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • NATO
  • US
  • UK
  • Africa
  • Afrique
  • CH

Categories

  • ABB
  • Alps
  • Basel
  • Bern
  • Chubb
  • Geneva
  • Glencore
  • Lausanne
  • Nestlé
  • Novartis
  • Roche
  • Switzerland
  • UBS
  • Vitol
  • Zürich
  • Zurich Insurance
Switzerland
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • NATO
  • US
  • UK
  • Africa
  • Afrique
  • CH

Browsing Tag

patients

46 posts
NNovartis
Novartis data at ESC Congress 2026 reinforce cardiovascular leadership and showcase progress in next-generation therapies
Read More

Novartis data at ESC Congress 2026 reinforce cardiovascular leadership and showcase progress in next-generation therapies

  • 2026-08-22
Novartis Pharma AG Late-breaking Phase IV VICTORION-CHALLENGE data will evaluate Leqvio® (inclisiran) vs. bempedoic acid in achieving LDL-C…
NNovartis
Novartis data at ESC Congress 2026 reinforce cardiovascular leadership and showcase progress in next-generation therapies
Read More

Novartis data at ESC Congress 2026 reinforce cardiovascular leadership and showcase progress in next-generation therapies

  • 2026-08-19
Novartis Pharma AG Late-breaking Phase IV VICTORION-CHALLENGE data will evaluate Leqvio® (inclisiran) vs. bempedoic acid in achieving LDL-C…
RRoche
Genprex Shares Rise After Collaboration With Roche Diagnostics
Read More

Genprex Shares Rise After Collaboration With Roche Diagnostics

  • 2026-08-03
Medical research ©rawpixel Genprex Inc. (NASDAQ:GNPX) shares gained 3% on Monday after the clinical-stage biotechnology company announced a…
RRoche
Brown Medicine Glass Bottles on Production Line
Read More

Roche, ViiV and Horizon most reputable pharmas in the world last year, say patient groups

  • 2026-07-30
Relationships between patient groups and pharma have become an accepted trend in healthcare and from a patient perspective,…
NNovartis
Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN
Read More

Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN

  • 2026-07-17
Novartis Pharma AG Fabhalta slowed eGFR decline by 48% vs placebo over two years, demonstrating kidney function preservation1 …
NNovartis
Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN
Read More

Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN

  • 2026-07-16
Novartis Pharma AG Fabhalta slowed eGFR decline by 48% vs placebo over two years, demonstrating kidney function preservation1 …
RRoche
AAIC26: Roche charts expanded course for Alzheimer’s therapy, touts long-term anti-amyloid impact
Read More

AAIC26: Roche charts expanded course for Alzheimer’s therapy, touts long-term anti-amyloid impact

  • 2026-07-16
Roche is eyeing a wider patient population for its anti-amyloid Alzheimer’s hopeful, trontinemab, as the space increasingly examines…
NNovartis
Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint
Read More

Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint

  • 2026-07-04
Novartis Pharma AG Ad hoc announcement pursuant to Art. 53 LR FORTITUDE study met primary and key secondary…
RRoche
Roche receives FDA approval for the first companion diagnostic to assess PTEN protein in people living with prostate cancer
Read More

Roche receives FDA approval for the first companion diagnostic to assess PTEN protein in people living with prostate cancer

  • 2026-07-02
F. Hoffmann-La Roche Ltd The new VENTANA PTEN (SP218) RxDx Assay fulfils an unmet medical need by helping…
RRoche
Roche receives FDA approval for the first companion diagnostic to assess PTEN protein in people living with prostate cancer
Read More

Roche receives FDA approval for the first companion diagnostic to assess PTEN protein in people living with prostate cancer

  • 2026-06-23
F. Hoffmann-La Roche Ltd The new VENTANA PTEN (SP218) RxDx Assay fulfils an unmet medical need by helping…
RRoche
Roche receives FDA approval for the first companion diagnostic to assess PTEN protein in people living with prostate cancer
Read More

Roche receives FDA approval for the first companion diagnostic to assess PTEN protein in people living with prostate cancer

  • 2026-06-15
F. Hoffmann-La Roche Ltd The new VENTANA PTEN (SP218) RxDx Assay fulfils an unmet medical need by helping…
NNovartis
Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint
Read More

Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint

  • 2026-06-13
Novartis Pharma AG Ad hoc announcement pursuant to Art. 53 LR FORTITUDE study met primary and key secondary…
Switzerland
www.europesays.com